Везде

RAS BiologyБиоорганическая химия Russian Journal of Bioorganic Chemistry

  • ISSN (Print) 0132-3423
  • ISSN (Online) 1998-2860

Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy

You can
PII
S1998286025020048-1
DOI
10.7868/S1998286025020048
Publication type
Review
Status
Published
Authors
A. O. Makarova
  • Affiliation:
    Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
    Real Target LLC
Volume/ Edition
Volume 51 / Issue number 2
Pages
233-254
Abstract
Today, cancer continues to be one of the most dangerous diseases, annually causing the deaths of >9 million people in the world. Therefore, new and more effective methods of cancer therapy are in demand. Monoclonal antibody-based immunotherapy has already shown its effectiveness; and antibody-drug conjugates (ADC), as one of its successful variants, have significant and not yet fully realized potential. ADCs are monoclonal antibodies bound by linkers to cytotoxic drugs. In many clinical trials and already in standard clinical practice ADCs have demonstrated significant advantages over combination therapy with unmodified antibodies and chemotherapy drugs. Due to new achievements in the field of molecular immunology and biotechnology, the potential of ADCs is assessed as a breakthrough, which will allow them to become the most sought-after anticancer drugs in the coming years. Owing to ADC, it has become possible to deliver drugs to tumor cells in a targeted manner without significant toxic effects on healthy tissues and organs. To date, 15 ADC drugs have been approved worldwide for use in clinic, and more than a hundred more drugs of this class are at various stages of clinical trials. At the same time, therapy using ADC is associated with certain side effects and limited efficacy, and therefore there is a need to develop more advanced conjugates. This review examines the history of the development of ADC as a therapeutic class of drugs, their structure, targets and mechanism of action. It also outlines the prospects and directions for further development of ADCs.
Keywords
конъюгаты антител с лекарством ADC моноклональные антитела цитотоксические агенты интернализация иммунотерапия таргетная доставка терапия рака
Date of publication
30.12.2025
Year of publication
2025
Number of purchasers
0
Views
58

References

  1. 1. Chen S., Cao Z., Prettner K., Kuhn M., Yang J., Jiao L., Wang Z., Li W., Geldsetzer P., Bärnighausen T., Bloom D.E., Wang C. // JAMA Oncol. 2023. V. 9. P. 465– 472. https://doi.org/10.1001/jamaoncol.2022.7826
  2. 2. Amjad M.T., Chidharla A., Kasi A. // StatPearls: StatPearls Publishing, 2023.
  3. 3. Esfahani K., Roudaia L., Buhlaiga N., Del Rincon S.V., Papneja N., Miller W.H., Jr. // Curr. Oncol. 2020. V. 27. P. 87–97. https://doi.org/10.3747/co.27.5223
  4. 4. Martinelli E., De Palma R., Orditura M., De Vita F., Ciardiello F. // Clin. Exp. Immunol. 2009. V. 158. P. 1–9. https://doi.org/10.1111/j.1365-2249.2009.03992.x
  5. 5. Yu S., Liu Q., Han X., Qin S., Zhao W., Li A., Wu K. // Exp. Hematol. Oncol. 2017. V. 6. P. 31. https://doi.org/10.1186/s40164-017-0091-4
  6. 6. Doronin I.I., Vishnyakova P.A., Kholodenko I.V., Ponomarev E.D., Ryazantsev D.Y., Molotkovskaya I.M., Kholodenko R.V. // BMC Cancer. 2014. T. 14. P. 295. https://doi.org/10.1186/1471-2407-14-295
  7. 7. Sterner R.C., Sterner R.M. // Blood Cancer J. 2021. V. 11. https://doi.org/10.1038/s41408-021-00459-7
  8. 8. Fu Z., Li S., Han S., Shi C., Zhang Y. // Signal Transduct. Target Ther. 2022. V. 7. P. 93. https://doi.org/10.1038/s41392-022-00947-7
  9. 9. Li J.H., Liu L., Zhao X.H. // Biomed. Pharmacother. 2024. V. 177. P. 117106. https://doi.org/10.1016/j.biopha.2024.117106
  10. 10. Sasso J.M., Tenchov R., Bird R., Iyer K.A., Ralhan K., Rodriguez Y., Zhou Q.A. // Bioconjug. Chem. 2023. V. 34. P. 1951–2000. https://doi.org/10.1021/acs.bioconjchem.3c00374
  11. 11. Petersen B.H., DeHerdt S.V., Schneck D.W., Bumol T.F. // Cancer Res. 1991. V. 51. P. 2286−2290.
  12. 12. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellström I., Hellström K.E. // Science. 1993. V. 261. P. 212–215. https://doi.org/10.1126/science.8327892
  13. 13. Beck A., Goetsch L., Dumontet C., Corvaïa N. // Nat. Rev. Drug Discov. 2017. V. 16. P. 315–337. https://doi.org/10.1038/nrd.2016.268
  14. 14. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Löwenberg B., Dombret H., Karanes C., Theobald M., Bennett J.M., Sherman M.L., Berger M.S., Eten C.B., Loken M.R., van Dongen J.J., Bernstein I.D., Appelbaum F.R., Mylotarg Study Group // J. Clin. Oncol. 2001. V. 19. P. 3244–3254. https://doi.org/10.1200/JCO.2001.19.13.3244
  15. 15. Guerra V.A., DiNardo C., Konopleva M. // Best Pract. Res. Clin. Haematol. 2019. V. 32. P. 145–153. https://doi.org/10.1016/j.beha.2019.05.008
  16. 16. Lambert J.M., Chari R.V. // J. Med. Chem. 2014. V. 57. P. 6949–6964. https://doi.org/10.1021/jm500766w
  17. 17. Baah S., Laws M., Rahman K.M. // Molecules. 2021. V. 26. P. 2943. https://doi.org/10.3390/molecules26102943
  18. 18. Wang Z., Li H., Gou L., Li W., Wang Y. // Acta Pharm. Sin. B. 2023. V. 13. P. 4025–4059. https://doi.org/10.1016/j.apsb.2023.06.015
  19. 19. Bhushan A., Misra P. // Curr. Oncol. Rep. 2024. V. 26. P. 1224–1235. https://doi.org/10.1007/s11912-024-01582-x
  20. 20. Chis A.A., Dobrea C.M., Arseniu A.M., Frum A., Rus L.L., Cormos G., Georgescu C., Morgovan C., Butuca A., Gligor F.G., Vonica-Tincu A.L. // Int. J. Mol. Sci. 2024. V. 25. P. 6969. https://doi.org/10.3390/ijms25136969
  21. 21. Riccardi F., Dal Bo M., Macor P., Toffoli G. // Front. Pharmacol. 2023. V. 14. P.1274088. https://doi.org/10.3389/fphar.2023.1274088
  22. 22. Staudacher A.H., Brown M.P. // Br. J. Cancer. 2017. V. 117. P. 1736–1742. https://doi.org/10.1038/bjc.2017.367
  23. 23. Kroemer G., Galassi C., Zitvogel L. // Nat. Immunol. 2022. V. 23. P. 487–500. https://doi.org/10.1038/s41590-022-01132-2
  24. 24. Bauzon M., Drake P.M., Barfield R.M., Cornali B.M., Rupniewski I., Rabuka D. // Oncoimmunol. 2019. V. 8. P. 1565859. https://doi.org/10.1080/2162402X.2019.1565859
  25. 25. Janke C., Magiera M.M. // Nat. Rev. Mol. Cell Biol. 2 020. V. 21. P. 307–326. https://doi.org/10.1038/s41580-020-0214-3
  26. 26. Burris H.A. // Am. Soc. Clin. Oncol. Educ. Book. 2012. P. 159–161. https://doi.org/10.14694/EdBook_AM.2012.32.109
  27. 27. Schwach J., Abdellatif M., Stengl A. // Front Biosci. (Landmark Ed). 2022. V. 27. P. 240. https://doi.org/10.31083/j.fbl2708240
  28. 28. Pommier Y. // Nat. Rev. Cancer. 2006. V. 6. P. 789– 802. https://doi.org/10.1038/nrc1977
  29. 29. Hartley J.A. // Expert Opin. Biol. Ther. 2021. V. 21. P. 931–943. https://doi.org/10.1080/14712598.2020.1776255
  30. 30. Yao H.P., Zhao H., Hudson R., Tong X.M., Wang M.H. // Drug Discov. Today. 2021. V. 26. P. 1857–1874. https://doi.org/10.1016/j.drudis.2021.06.012
  31. 31. Yin W., Rogge M. // Clin. Transl. Sci. 2019. V. 12. P. 98–112. https://doi.org/10.1111/cts.12624
  32. 32. Ramanjulu J.M., Pesiridis G.S., Yang J., Concha N., Singhaus R., Zhang S.Y., Tran J.L., Moore P., Lehmann S., Eberl H.C., Muelbaier M., Schneck J.L., Clemens J., Adam M., Mehlmann J., Romano J., Morales A., Kang J., Leister L., Graybill T.L., Charnley A.K., Ye G., Nevins N., Behnia K., Wolf A.I., Kasparcova V., Nurse K., Wang L., Puhl A.C., Li Y., Klein M., Hopson C.B., Guss J., Bantscheff M., Bergamini G., Reilly M.A., Lian Y., Duffy K.J., Adams J., Foley K.P., Gough P.J., Marquis R.W., Smothers J., Hoos A., Bertin J. // Nature. 2018. V. 564. P. 439–443. https://doi.org/10.1038/s41586-018-0705-y
  33. 33. Wei Y., Xiang H., Zhang W. // Front. Pharmacol. 2022. V. 13. P. 970553. https://doi.org/10.3389/fphar.2022.970553
  34. 34. Youle R.J., Strasser A. // Cell Biol. 2008. V. 9. P. 47–59. https://doi.org/10.1038/nrm2308
  35. 35. Almaliti J., Miller B., Pietraszkiewicz H., Glukhov E., Naman C.B., Kline T., Hanson J., Li X., Zhou S., Valeriote F.A., Gerwick W.H. // Eur. J. Med. Chem. 2019. V. 161. P. 416–432. https://doi.org/10.1016/j.ejmech.2018.10.024
  36. 36. Simmons J.K., Burke P.J., Cochran J.H., Pittman P.G., Lyon R.P. // Toxicol. Appl. Pharmacol. 2020. V. 392. P. 114932. https://doi.org/10.1016/j.taap.2020.114932
  37. 37. Jain N., Smith S.W., Ghone S., Tomczuk B. // Pharm. Res. 2015. V. 32. P. 3526–3540. https://doi.org/10.1007/s11095-015-1657-7
  38. 38. Anderson N.M., Simon M.C. // Curr. Biol. 2020. V. 30. P. R921–R925. https://doi.org/10.1016/j.cub.2020.06.081
  39. 39. Lu J., Jiang F., Lu A., Zhang G. // Int. J. Mol. Sci. 2016. V. 17. P. 561. https://doi.org/10.3390/ijms17040561
  40. 40. Kovtun Y.V., Goldmacher V.S. // Cancer Lett. 2007. V. 255. P. 232–240. https://doi.org/10.1016/j.canlet.2007.04.010
  41. 41. Walsh S.J., Bargh J.D., Dannheim F.M., Hanby A.R., Seki H., Counsell A.J., Ou X., Fowler E., Ashman N., Takada Y., Isidro-Llobet A., Parker J.S., Carroll J.S., Spring D.R. // Chem. Soc. Rev. 2021. V. 50. P. 1305– 1353. https://doi.org/10.1039/d0cs00310g
  42. 42. von Witting E., Hober S., Kanje S. // Bioconjug. Chem. 2021. V. 32. P. 1515–1524. https://doi.org/10.1021/acs.bioconjchem.1c00313
  43. 43. Wei C., Zhang G., Clark T., Barletta F., Tumey L.N., Rago B., Hansel S., Han X. // Anal. Chem. 2016. V. 88. P. 4979–4986. https://doi.org/10.1021/acs.analchem.6b00976
  44. 44. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., Lu Y., Meng Y.G., Ng C., Yang J., Lee C.C., Duenas E., Gorrell J., Katta V., Kim A., McDorman K., Flagella K., Venook R., Ross S., Spencer S.D., Wong W.L., Lowman H.B., Vandlen R., Sliwkowski M.X., Scheller R.H., Polakis P., Mallet W. // Nat. Biotechnol. 2008. V. 26. P. 925–932. https://doi.org/10.1038/nbt.1480
  45. 45. Axup J.Y., Bajjuri K.M., Ritland M., Hutchins B.M., Kim C.H., Kazane S.A., Halder R., Forsyth J.S., Santidrian A.F., Stafin K., Lu Y., Tran H., Seller A.J., Biroc S.L., Szydlik A., Pinkstaff J.K., Tian F., Sinha S.C., Felding-Habermann B., Smider V.V., Schultz P.G. // Proc. Natl. Acad. Sci. USA. 2012. V. 109. P. 16101– 16106. https://doi.org/10.1073/pnas.1211023109
  46. 46. Rabuka D., Rush J.S., deHart G.W., Wu P., Bertozzi C.R. // Nat. Protoc. 2012. V. 7. P. 1052–1067. https://doi.org/10.1038/nprot.2012.045
  47. 47. Zhu Z., Ramakrishnan B., Li J., Wang Y., Feng Y., Prabakaran P., Colantonio S., Dyba M.A., Qasba P.K., Dimitrov D.S. // MAbs. 2014. V. 6. P. 1190–1200. https://doi.org/10.4161/mabs.29889
  48. 48. Schumacher F.F., Nunes J.P., Maruani A., Chudasama V., Smith M.E., Chester K.A., Baker J.R., Caddick S. // Org. Biomol. Chem. 2014. V. 12. P. 7261– 7269. https://doi.org/10.1039/c4ob01550a
  49. 49. Metrangolo V., Engelholm L.H. // Cancers (Basel). 2024.V. 16. P. 447. https://doi.org/10.3390/cancers16020447
  50. 50. Hughes B. // Nat. Rev. Drug Discov. 2010. V. 9. P. 665–667. https://doi.org/10.1038/nrd3270
  51. 51. Zhang J., Woods C., He F., Han M., Treuheit M.J., Volkin D.B. // Biochemistry. 2018. V. 57. P. 5466–5479. https://doi.org/10.1021/acs.biochem.8b00575
  52. 52. Teicher B.A., Chari R.V. // Clin. Cancer Res. 2011. V. 17. P. 6389–6397. https://doi.org/10.1158/1078-0432.CCR-11-1417
  53. 53. Kholodenko R.V., Kalinovsky D.V., Doronin I.I., Ponomarev E.D., Kholodenko I.V. // Curr. Med. Chem. 2019. V. 26. P. 396–426. https://doi.org/10.2174/0929867324666170817152554
  54. 54. Lou H., Cao X. // Cancer Commun. (Lond). 2022. V. 42. P. 804–827. https://doi.org/10.1002/cac2.12330
  55. 55. Kholodenko V., Kalinovsky D.V., Svirshchevskaya E.V., Doronin I.I., Konovalova M.V., Kibardin A.V., Shamanskaya T.V., Larin S.S., Deyev S.M., Kholodenko R.V. // Molecules. 2019. V. 24. P. 3835. https://doi.org/10.3390/molecules24213835
  56. 56. Hussack G., Ryan S., van Faassen H., Rossotti M., MacKenzie C.R., Tanha J. // PLoS One. 2018. V. 13. P.e0208978. https://doi.org/10.1371/journal.pone.0208978
  57. 57. Muyldermans S. // Annu. Rev. Biochem. 2013. V. 82. P. 775–797. https://doi.org/10.1146/annurev-biochem-063011-092449
  58. 58. Thakur A., Huang M., Lum L.G. // Blood Rev. 2018. V. 32. P. 339–347. https://doi.org/10.1016/j.blre.2018.02.004
  59. 59. Newman M.J., Benani D.J. // J. Oncol. Pharm. Pract. 2016. V. 22. P. 639–645. https://doi.org/10.1177/1078155215618770
  60. 60. Zeng H., Ning W., Liu X., Luo W., Xia N. // Front. Med. 2024. V. 18. P. 597–621. https://doi.org/10.1007/s11684-024-1072-8
  61. 61. Strohl W.R. // Protein Cell. 2018. V. 9. P. 86–120. https://doi.org/10.1007/s13238-017-0457-8
  62. 62. Esapa B., Jiang J., Cheung A., Chenoweth A., Thurston D.E., Karagiannis S.N. // Cancers (Basel). 2023. V. 15. P. 1845. https://doi.org/10.3390/cancers15061845
  63. 63. Ingle G.S., Chan P., Elliott J.M., Chang W.S., Koeppen H., Stephan J.P., Scales S.J. // Br. J. Haematol. 2008. V. 140. P. 46–58. https://doi.org/10.1111/j.1365-2141.2007.06883.x
  64. 64. Short N.J., Kantarjian H. // Lancet Haematol. 2023. V. 10. P. e382–e388. https://doi.org/10.1016/S2352-3026 (23)00064-9
  65. 65. Xing L., Liu Y., Liu J. // Cancers (Basel). 2023. V. 15. P. 2240. https://doi.org/10.3390/cancers15082240
  66. 66. Burke J.M., Morschhauser F., Andorsky D., Lee C., Sharman J.P. // Expert. Rev. Clin. Pharmacol. 2020. V. 13. P. 1073–1083. https://doi.org/10.1080/17512433.2020.1826303
  67. 67. Criscitiello C., Morganti S., Curigliano G. // J. Hematol. Oncol. 2021. V. 14. P. 20. https://doi.org/10.1186/s13045-021-01035-z
  68. 68. de Azambuja E., Bedard P.L., Suter T., PiccartGebhart M. // Target Oncol. 2009. V. 4. P. 77–88. https://doi.org/10.1007/s11523-009-0112-2
  69. 69. Shvartsur A., Bonavida B. // Genes Cancer. 2015. V. 6. P. 84–105. https://doi.org/10.18632/genesandcancer.40
  70. 70. Ordu M., Karaaslan M., Sirin M.E., Yilmaz M. // North Clin. Istanb. 2023. V. 10. P. 583–588. https://doi.org/10.14744/nci.2023.36034
  71. 71. Gonzalez T., Muminovic M., Nano O., Vulfovich M. // Int. J. Mol. Sci. 2024. V. 25. P. 1046. https://doi.org/10.3390/ijms25021046
  72. 72. Ahmadi S.E., Shabannezhad A., Kahrizi A., Akbar A., Safdari S.M., Hoseinnezhad T., Zahedi M., Sadeghi S., Mojarrad M.G., Safa M. // Biomark Res. 2023. V. 11. P. 60. https://doi.org/10.1186/s40364-023-00504-6
  73. 73. Rui R., Zhou L., He S. // Front. Immunol. 2023. V. 14. P. 1212476. https://doi.org/10.3389/fimmu.2023.1212476
  74. 74. Anderson AC, Joller N, Kuchroo VK. // Immunity. 2016. V. 44 P.989-1004. https://doi.org/10.1016/j.immuni.2016.05.001
  75. 75. Negative A., Year S.S., Jeter A., Saragovi H.U. // Front. Oncol. 2023. V. 13. P. 1261090. https://doi.org/10.3389/fonc.2023.1261090
  76. 76. Philippova J., Shevchenko J., Sennikov S. // Front. Immunol. 2024. V. 15. P. 1371345. https://doi.org/10.3389/fimmu.2024.1371345
  77. 77. Nazha B., Inal C., Owonikoko T.K. // Front. Oncol. 2020. V. 10. P. 1000. https://doi.org/10.3389/fonc.2020.01000
  78. 78. Machy P., Mortier E., Birklé S. // Front. Pharmacol. 2023. V. 14. P. 1249929. https://doi.org/10.3389/fphar.2023.1249929
  79. 79. Ivanov N.S., Kachanov D.Y., Larin S.S., Mollaev M.D., Konovalov D.M., Shamanskaya T.V. // Russ. J. Pediatr. Hematol. Oncol. 2021. V. 8. P. 47–59.
  80. 80. Orsi G., Barbolini M., Ficarra G., Tazzioli G., Manni P., Petrachi T., Mastrolia I., Orvieto E., Spano C., Prapa M., Kaleci S., D’Amico R., Guarneri V., Dieci M.V., Cascinu S., Conte P., Piacentini F., Dominici M. // Oncotarget. 2017. V. 8. P. 31592–31600. https://doi.org/10.18632/oncotarget.16363
  81. 81. Ahmed M., Cheung N.K. // FEBS Lett. 2014. V. 588. P. 288–297. https://doi.org/10.1016/j.febslet.2013.11.030
  82. 82. Kholodenko I.V., Kalinovsky D.V., Doronin I.I., Deyev S.M., Kholodenko R.V. // J. Immunol. Res. 2018. V. 2018. P. 7394268. https://doi.org/10.1155/2018/7394268
  83. 83. Ploessl C., Pan A., Maples K.T., Lowe D.K. // Ann. Pharmacother. 2016. V. 50. P. 416–422. https://doi.org/10.1177/1060028016632013
  84. 84. Kalinovsky D.V., Kibardin A.V., Kholodenko I.V., Svirshchevskaya E.V., Doronin I.I., Konovalova M.V., Grechikhina M.V., Rozov F.N., Larin S.S., Deyev S.M., Kholodenko R.V. // J. Immunother. Cancer. 2022. V. 10. P. e004646. https://doi.org/10.1136/jitc-2022-004646
  85. 85. Kalinovsky D.V., Kholodenko I.V., Kibardin A.V., Doronin I.I., Svirshchevskaya E.V., Ryazantsev D.Y., Konovalova M.V., Rozov F.N., Larin S.S., Deyev S.M., Kholodenko R.V. // Int. J. Mol. Sci. 2023. V. 24. P. 1239. https://doi.org/10.3390/ijms24021239
  86. 86. Kalinovsky D.V., Kholodenko I.V., Svirshchevskaya E.V., Kibardin A.V., Ryazantsev D.Y., Rozov F.N., Larin S.S., Deyev S.M., Kholodenko R.V. // Curr. Issues Mol. Biol. 2023. V. 45. P. 8112–8125. https://doi.org/10.3390/cimb45100512
  87. 87. Liu K., Li M., Li Y., Li Y., Chen Z., Tang Y., Yang M., Deng G., Liu H. // Mol. Cancer. 2024. V. 23. P. 62. https://doi.org/10.1186/s12943-024-01963-7
  88. 88. Ma X., Wang M., Ying T., Wu Y. // Antib. Ther. 2024. V. 7. P. 114–122. https://doi.org/10.1093/abt/tbae005
  89. 89. Su Z., Xiao D., Xie F., Liu L., Wang Y., Fan S., Zhou X., Li S. // Acta Pharm. Sin. B. 2021. V. 11. P. 3889–3907. https://doi.org/10.1016/j.apsb.2021.03.042
QR
Translate

Индексирование

Scopus

Scopus

Scopus

Crossref

Scopus

Higher Attestation Commission

At the Ministry of Education and Science of the Russian Federation

Scopus

Scientific Electronic Library